YOUR GUT MICROBIOME AND WEIGHT LOSS
Bifidobacterium animalis ssp lactis (B-420™)
A probiotic strain to help individuals achieve body weight control.
A daily dose of 10 billion CFU of Bifidobacterium animalis ssp lactis (B-420™) has been shown in a six-month clinical trial to help:
- Control total body fat
- Reduce waist circumference
- Control body weight
- Control abdominal fat
- Promote short-chain fatty acid (SCFA) production
The Microbiome and Weight Connection
A growing body of literature is substantiating the link between the intestinal microbiota and the regulation of body weight and body fat mass. Dysbiosis and a lack of microbial diversity may contribute to altered metabolic function resulting in a propensity to gain weight more easily and an increased visceral fat mass. Altered microbial diversity may lead to increased energy harvest (more efficient extraction of energy from food) and storage from the diet, reduced barrier function, altered satiety signalling and metabolic endotoxaemia.
Genomic content and diversity in the microbiome has been shown to be different in obese individuals as compared to lean individuals in pre-clinical investigations. In one trial, microbiome samples from twins discordant for obesity (one lean, one with obesity) were transferred to mice. Mice receiving the ‘obese microbiome’ sample gained significant body fat compared to recipients of the ‘lean microbiome’2 (Figure 1).
Pre-Clinical Research Highlights – B-420™
- Metabolic health benefits
- Improved glycaemic response.
- Reduced circulating zonulin levels
- Improvement to tight junction integrity and protection against
E.coli induced intestinal damage (in vitro evidence).
- Demonstrated ability to reduce systemic and hepatic inflammation
through reduction of inflammatory markers: high-sensitivity
C-reactive protein (hsCRP), tumour-necrosis factor-α (TNF-α),
interleukin-1β (IL-1β) and Interleukin 6 (IL-6).
Figure 1: The transplantation of an ‘obese microbiome’ vs. ‘lean microbiome’ from twins caused weight differences in mice.
Inflammation: An Underlying Driver of Obesity
Chronic low-grade inflammation is a major factor in the development of obesity-related metabolic disturbances, and may be caused by dietary factors, as well as abnormally increased gut permeability to bacteria and their by-products. Circulating endotoxins such as lipopolysaccharides (LPS) are a major cause of inflammation and may contribute to metabolic disturbances, such as visceral fat deposition, glucose intolerance, oxidative stress and hepatic insulin resistance.
Probiotic Support for Weight Management
A growing body of evidence supports the use of probiotics in weight management to alter the ‘obese microbiome’ to that of a healthy lean individual. As shown in Figure 2, clinically researched probiotic strain Bifidobacterium animalis ssp lactis (B-420™) helps support body weight regulation through:
- Modification of the gut microbiota composition.
- Improvement of gut integrity to prevent the translocation of inflammatory molecules from the gut.
- Increasing short chain fatty acid (SCFA) production, which increases glucagon-like peptide-1 (GLP-1) for glycaemic control, and peptide YY (PYY) secretion to support satiety.
Figure 2: The Bifidobacterium animalis ssp lactis (B-420™) probiotic strain influences the composition of the intestinal microbiome and epithelial barrier function and may enhance satiety signalling, all of which may play a role in the regulation of body weight and fat mass.
Human Clinical Research – B-420™
The effect of Bifidobacteria animalis ssp lactis (B-420™) was investigated with or without fibre in 225 overweight or obese patients. The patients were divided into four groups and consumed: placebo, 10 billion CFU B-420™, fibre alone or the same dose of probiotic with fibre daily for six months.
The primary outcome measure was the changes to body fat mass from baseline to treatment end, and the results demonstrated a significant difference between the B-420™ and placebo groups in changes to total body fat mass (p = 0.002), trunk fat mass (p = 0.0002) and android fat mass (p = 0.004) in the per protocol (PP) population (the patient group that adhered to the clinical trial instructions
correctly without deviation). Furthermore, the B-420™ group showed a trend towards a reduction in body weight (p = 0.15), and both the B-420™ and B-420™ with fibre groups showed a difference in weight circumference compared to placebo (-2.4 cm, p = 0.004 and -2.6 cm, p = 0.047, respectively).